MedTrace Logo

Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer

NCT03072641 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-03-07

No results posted yet for this study

Summary

The purpose of the study is to determine if probiotic bacteria have a beneficial effect on the colon cancer-associated microbiota and epigenetic alterations in colon cancer. Dietary supplementation consists of two ProBion Clinica tablets, yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.

Conditions

Interventions

DIETARY_SUPPLEMENT

ProBion Clinica

Sponsors & Collaborators

  • DuPont Nutrition and Health

    collaborator INDUSTRY

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Yvonne A Wettergren, PhD · Dept. of surgery, Sahlgrenska Univ. Hospital, Gothenburg, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-03
Primary Completion
2016-03-31
Completion
2016-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03072641 on ClinicalTrials.gov